Biopharmaceutics is a pivotal field within the Food and Drug Administration's (FDA) purview, where the intersection of biology and pharmaceuticals takes center stage. This discipline focuses on the study of how drugs are absorbed, distributed, metabolized, and excreted by the body, with a keen eye on the biological factors influencing drug performance.
The FDA plays a crucial role in evaluating the safety and efficacy of biopharmaceuticals, ensuring that these innovative drugs meet rigorous standards before reaching the market. This involves a comprehensive assessment of the biological and chemical properties of these compounds, understanding their behavior in the human body, and predicting their therapeutic impact.
The dynamic landscape of biopharmaceutics aligns with the FDA's commitment to advancing public health by fostering the development of cutting-edge therapies. By staying at the forefront of scientific advancements, the FDA continues to navigate the evolving terrain of biopharmaceutics, contributing to the approval of novel, life-changing treatments that meet the highest standards of quality and effectiveness.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia